Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 …
A Krämer, T Bochtler, C Pauli, KK Shiu, N Cook… - The Lancet, 2024 - thelancet.com
Background Patients with unfavourable subset cancer of unknown primary (CUP) have a
poor prognosis when treated with standard platinum-based chemotherapy. Whether first-line …
poor prognosis when treated with standard platinum-based chemotherapy. Whether first-line …
A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary
Abstract Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic
challenge due to biological heterogeneity and poor responses to standard chemotherapy …
challenge due to biological heterogeneity and poor responses to standard chemotherapy …
Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies
X Liu, H Jiang, X Wang - Biosensors, 2024 - mdpi.com
Cancers of unknown primary (CUP) exhibit significant cellular heterogeneity and
malignancy, which poses significant challenges for diagnosis and treatment. Recent years …
malignancy, which poses significant challenges for diagnosis and treatment. Recent years …
Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management
E Rassy, FA Greco, N Pavlidis - The Lancet, 2024 - thelancet.com
Cancer of unknown primary (CUP) accounts for 2–3% of all metastatic cancers and
encompasses a diverse array of metastatic cancers without an identifiable primary after …
encompasses a diverse array of metastatic cancers without an identifiable primary after …
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer?
R Huey, K Raghav - The Lancet Oncology, 2024 - thelancet.com
The Article by Xin Liu and colleagues1 published in The Lancet Oncology is the first
randomised trial showing a benefit of site-specific therapy over empirical chemotherapy …
randomised trial showing a benefit of site-specific therapy over empirical chemotherapy …
Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary
RJ Rebello, A Posner, R Dong, OWJ Prall… - medRxiv, 2024 - medrxiv.org
Genomics holds promise for precision treatment and identifying the primary tissue of origin
(TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and …
(TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and …
Cancer of Unknown Primary Site: A New Era of Practice-Changing Approaches to Diagnosis, Staging, and Precision Therapy
FA Greco - JCO Oncology Advances, 2024 - ascopubs.org
The enigmatic syndrome of metastatic cancer of unknown primary (CUP) site has frustrated
physicians and patients for decades. There has been debate whether CUP is a single …
physicians and patients for decades. There has been debate whether CUP is a single …
CUPiD: A cfDNA methylation-based tissue-of-origin classifier for Cancers of Unknown Primary
D Rothwell, AM Conway, S Pearce, A Clipson, S Hill… - 2023 - researchsquare.com
Abstract Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic
challenge due to biological heterogeneity and poor responses to standard chemotherapy …
challenge due to biological heterogeneity and poor responses to standard chemotherapy …
[HTML][HTML] Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies
G Zaun, S Borchert, M Metzenmacher, S Lueong… - European Journal of …, 2024 - Elsevier
Purpose Current guidelines recommend combination chemotherapy for treatment of patients
with unfavorable cancer of unknown primary (CUP). Biomarker-guided targeted therapies …
with unfavorable cancer of unknown primary (CUP). Biomarker-guided targeted therapies …